AbbVie Inc. is 10.3x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $38.62 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALNY | ABBV |
|---|---|---|
| Market cap | $38.62 B | $399.47 B |
| US-listed rank | #396 | #28 |
| Revenue (latest FY) | $3.71B | $61.16B |
| Net income (latest FY) | $313.75M | $4.23B |
| Net margin | 8.4% | 6.9% |
| P/E (trailing FY) | 123.1 | 94.5 |
| SEC filings | 1,651 | 1,008 |
AbbVie Inc. is 10.3x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $38.62 B).
In their latest fiscal years, ALNYLAM PHARMACEUTICALS, INC. reported $3.71B in revenue while AbbVie Inc. reported $61.16B.
Full pages: ALNYLAM PHARMACEUTICALS, INC. and AbbVie Inc., or browse the full rankings.